Visium Asset Management’s Atara Biotherapeutics ATRA Stock Holding History

Visium Asset Management’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-24,249	Closed	-$11.5M	–	356
2016 Q1	$11.5M	Sell	24,249 -4,656	-16%	-$2.1M	0.2%	130
2015 Q4	$19.1M	Sell	28,905 -4,393	-13%	-$3.32M	0.29%	73
2015 Q3	$26.2M	Sell	33,298 -2,883	-8%	-$3.52M	0.36%	51
2015 Q2	$47.7M	Sell	36,181 -219	-0.6%	-$251K	0.68%	26
2015 Q1	$37.8M	Buy	36,400 +8,794	+32%	+$5.81M	0.56%	31
2014 Q4	$18.5M	Buy	+27,606	New	+$16.9M	0.26%	72

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Visium Asset Management's ATRA Position: Q2 2016 in Review

Visium Asset Management sold out of Atara Biotherapeutics (ATRA) in Q2 2016, closing a stake of 24,249 shares — an estimated $11.5M sold.

Visium Asset Management first reported a position in ATRA in Q4 2014 and held it in 6 quarters. The position peaked at $47.7M in Q2 2015. 74 funds tracked by Wall St. Rank hold ATRA as of Q2 2016.

Visium Asset Management reported no remaining Atara Biotherapeutics position as of Q2 2016 after selling out during the quarter.
Visium Asset Management sold 24,249 Atara Biotherapeutics shares in Q2 2016, an estimated $11.5M.
Visium Asset Management first reported a position in Atara Biotherapeutics in Q4 2014 and held it in 6 quarters.
Visium Asset Management's Atara Biotherapeutics position peaked at $47.7M in Q2 2015.
74 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2016.

Based on Visium Asset Management's 13F filing for Q2 2016, filed 12 Aug 2016.